Baird analyst Michael Halloran downgrades Evoqua Water Techs (NYSE:AQUA) from Outperform to Neutral and maintains $49 price target.
Genentech’s Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
Genentech, a unit of Roche Holdings AG (OTC:RHHBY), announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival…